Company profile: Siolta Therapeutics
1.1 - Company Overview
Company description
- Provider of therapeutic microbial consortia and live biotherapeutic products to prevent and treat inflammatory and atopic diseases. Offers the Precision Symbiotics Platform integrating clinical data, bioinformatics, and microbial science; STMC-103H in phase 2 for atopic disease prevention; maternal-infant axis therapeutics; diagnostics for patient stratification; and GMP manufacturing for clinical advancement.
Products and services
- STMC-103H: A clinical-stage, multi-strain live biotherapeutic constructed to prevent atopic diseases, currently in phase 2 development and built as a microbial consortium for prophylactic use
- Precision Symbiotics Platform: A custom-engineered platform integrating clinical datasets, bioinformatics pipelines, and microbial science to architect live biotherapeutic products, engineering therapeutic microbial consortia with data-guided design
- Live Biotherapeutic Products for Maternal-Infant Axis: Indication-specific products developed to target diseases in the maternal-infant axis, including atopic diseases, women’s health, and rare pediatric indications using therapeutic microbial consortia
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Siolta Therapeutics
Personal Genome Diagnostics
HQ: United States
Website
- Description: Provider of patient-specific cancer genome analysis tools and comprehensive genomic profiling kits, including PGDx elio tissue complete (FDA cleared, CE-IVD marked) for in-house tumor profiling of over 500 genes identifying somatic mutations (SNVs, indels, TMB, MSI, select amplifications/translocations); PGDx elio plasma complete liquid biopsy for research across over 500 genes (SNVs, indels, bTMB, MSI, LOH); and PGDx elio plasma focus targeting 33 cancer genes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Personal Genome Diagnostics company profile →
Monogram Biosciences
HQ: United States
Website
- Description: Provider of innovative products to guide and improve treatment of infectious diseases, cancer, and other serious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Monogram Biosciences company profile →
Grail
HQ: United States
Website
- Description: Provider of pan-cancer screening tests designed to detect cancers at an early stage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Grail company profile →
Veritas Intercontinental
HQ: Spain
Website
- Description: Provider of whole genome sequencing and interpretation for consumers and physicians, offering myGenome for disease prevention and healthcare management, myPrenatal non-invasive prenatal testing, myNewborn screening for early childhood onset diseases, hereditary cardiovascular and cancer risk genetic testing, and whole genome and exome sequencing for complex cases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Veritas Intercontinental company profile →
CDx Diagnostics
HQ: United States
Website
- Description: Provider of cancer-prevention diagnostic systems that detect pre-cancerous cells, including WATS3D, combining wide-area tissue sampling, 3D imaging, AI analysis, and GI pathologist review for Barrett’s esophagus and dysplasia; OralCDx, a non-invasive oral brush biopsy with AI-enabled tissue analysis; and laboratory cytopathology and histopathology services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CDx Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Siolta Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Siolta Therapeutics
2.2 - Growth funds investing in similar companies to Siolta Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Siolta Therapeutics
4.2 - Public trading comparable groups for Siolta Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →